Omalizumab is an IgE inhibitor, there was a comparison of effectiveness among omalizumab, mepolizumab and dupilumab in asthma patients (35), however, further clinical trials quantifying therapeutic response of omalizumab on AA patients with high IgE levels are warranted. The gene discussed is IGHE; the disease is asthma.